NIH SBIR/STTR Phase II: Turning Phase I Feasibility into a Funded Continuation

Why Phase II Is Not Phase I, Scaled Up

Phase I asked: can this work? Phase II asks something different: will this work at sufficient scale to reach commercialization? The review criteria shift in emphasis. In Phase I, Technical Merit and Scientific/Technical Merit carry the heaviest weight. In Phase II, Commercialization Potential picks up roughly co-equal status with technical merit. Reviewers reading a Phase II application are explicitly asked to evaluate whether a real product or service is likely to emerge — not just whether the underlying science is interesting.

This matters because many Phase I applicants come from academic labs or research-focused small businesses where the proof-of-concept is the goal. Phase II funding is meant to de-risk the translation from concept to market. If your application reads like it is proposing another round of interesting research with no clear path to a product, it will score accordingly. The reviewer sitting on an SBIR/STTR study section has usually seen many applications that do excellent science but never get close to a customer. They have learned to be skeptical of that pattern.

One concrete signal reviewers watch for: does the Phase II application name a specific regulatory pathway? If your product will require FDA clearance, say so, name the pathway — 510(k), De Novo, PMA, IND/BLA — and describe what the Phase II work contributes to meeting that pathway's evidentiary bar. If the regulatory question is genuinely unresolved at this stage, acknowledge that and describe how you will resolve it during Phase II. Avoiding the topic entirely is one of the clearest signals that an applicant has not thought seriously about what commercialization actually requires.

The Phase I Self-Assessment: Your Most Underrated Section

Phase II applications require a Phase I summary — a self-assessment of what you accomplished, what you did not accomplish, and what the results mean for the Phase II direction. Most applicants treat this as a deliverables table. It should be a strategic argument.

The frame you want is: here is what we set out to test. Here is what the data show. Here is why these results justify the specific Phase II direction we are now proposing. If any Phase I aim produced unexpected findings, address them directly. Reviewers notice when a Phase I summary describes a slightly different set of accomplishments than the original Phase I aims — they will check — so be transparent about pivots and explain why the pivot improves your path to commercialization rather than undermining it.

Quantitative results consistently distinguish strong Phase I summaries from weak ones. "We demonstrated feasibility of X" is weaker than "We achieved an EC50 of 3.2 nM in the target assay, meeting our go-forward criterion of <10 nM." Reviewers are pattern-matching for evidence that you actually did what you said you would do, and precise numbers do this more efficiently than narrative. If you set explicit go/no-go criteria in your Phase I proposal, this is where you report whether you met them and what that means for the Phase II direction.

The Commercialization Plan: Where Most Applications Lose Ground

The commercialization plan is the section where Phase II applications most often fall short. It is also the section that academic PIs and early-stage company founders tend to write last, in a rush, with language borrowed from business plan templates.

A reviewer scoring the Commercialization Potential criterion is asking three questions: Is there an identifiable market for this product or service? Does the applicant have a plausible path to that market? And is the Phase II work actually aligned with reaching it?

The most common failure is a plan that describes the total addressable market in dollar terms without connecting it to the specific product proposed. Saying that the U.S. medical device market is $200 billion is not a commercialization plan. What reviewers want is specificity: who are the first customer categories? What will it cost to produce the product at initial-sales scale? Is there IP protection in place or in process? Who are the likely partners or acquirers, and have you spoken to any of them?

A credible commercialization plan does not need to be long — four to six well-organized paragraphs often outperform eight pages of market data. But it needs to be specific. If you have a letter of intent from a potential customer or licensing partner, include it in the appendix and reference it in the plan. If you have spoken to a program officer at a relevant federal agency about follow-on procurement, say so. Reviewers are looking for evidence that you have done commercial homework, not just scientific homework, and the most credible evidence is documentation of actual conversations with actual potential customers.

Technical Approach: Milestones That Reviewers Believe

Phase II technical approaches need milestones that function as Go/No-Go decisions, not just deliverables. This is one of the few places where NIH grant writing conventions and SBIR/STTR program expectations genuinely diverge from standard R01 practice.

In a standard R01, aims are expected to be somewhat independent of each other. In Phase II, milestones should build on each other in a way that resembles a development pipeline — because that is what they are. But each milestone should include an explicit decision criterion: if the criterion is not met, what happens? Do you pursue a backup formulation? Narrow the target population? File for Phase IIB bridge funding? Reviewers who sit on SBIR/STTR study sections regularly see applications where the milestones are vague enough that the project would never technically fail. That pattern is a concern signal, not a sign of a flexible plan.

"Optimize the formulation" is not a milestone. "Achieve <10% batch-to-batch variability in particle size at the 100-gram scale, with >90% retention of activity after 30-day storage at 4°C" is a milestone. The specificity signals that the applicant has thought through what success actually looks like and how to measure it. The Go/No-Go frame also implicitly tells reviewers that you will stop spending NIH money if the project is not working — which is exactly what the program wants to believe.

The number of aims in Phase II can be slightly larger than in Phase I, but scope creep is a real scoring risk. A Phase II award is typically two years, with budgets in the range described below. If your aims list suggests a team of 15 people working for four years, reviewers will note the mismatch. Three focused, milestone-driven aims will almost always outperform five broadly described ones at the same budget level.

Budget Considerations: From Modular to Real Numbers

Phase II SBIR/STTR budgets are non-modular: you justify every line. As of recent fiscal years, standard Phase II budgets can run to roughly $1.7 million in total costs over two years, with some institutes allowing higher amounts for specific programs. Check the parent SBIR/STTR funding opportunity announcement and your target IC's supplementary guidance before setting a number. The ceiling varies by institute and changes, so do not assume the figure from a colleague's award is still current.

The biggest budget mistake in Phase II applications is under-budgeting for commercialization activities. Regulatory consulting, IP licensing work, manufacturing process development, and early customer validation are all legitimate Phase II costs. Many applicants budget heavily for personnel and equipment tied to technical milestones and then list commercialization-related costs as a vague line item. This inconsistency signals that the applicant has not worked through what the commercial path actually requires at this stage.

Your budget justification should explain every line, but the commercialization-related lines deserve a few extra sentences: describe what the activity is, why it happens at this stage, and how it connects to the milestone it supports. A reviewer who cannot trace a budget line to a milestone will often flag it as a concern, and in Phase II that flag can move the score more than in Phase I because the award is larger and the commercial stakes are higher. When in doubt, call your program officer before you set the budget total.

The Most Common Phase II Mistakes

Frequently Asked Questions